{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:12:31Z","timestamp":1789665151180,"version":"4.0.1"},"reference-count":69,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:p>Obesity is a chronic condition that causes significant morbidity and mortality in people in the United States and around the world. Traditional means of weight loss include diet, exercise, behavioral modifications, and surgery. New weight loss medications, glucagon-like peptide-1 receptor agonists, are revolutionizing the management of weight loss but have implications for fertility and pregnancy. Obesity is associated with infertility and may affect response to ovulation induction medications. In pregnancy, obesity increases the risks of spontaneous abortion, birth defects, gestational diabetes, hypertensive disorders of pregnancy, cesarean delivery, and stillbirth. Lifestyle changes alone for weight loss have not improved outcomes. Glucagon-like peptide-1 receptor agonists and new medications targeting gut hormones can help people achieve their weight loss goals but are contraindicated in pregnancy. Obstetrician\u2013gynecologists should work with patients to manage these medications before they become pregnant, between pregnancies, and after delivery.<\/jats:p>","DOI":"10.1097\/aog.0000000000005825","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T22:01:19Z","timestamp":1737669679000},"page":"286-296","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Role of Glucagon-Like Peptide-1 Receptor Agonists in People With Infertility and Pregnancy"],"prefix":"10.1097","volume":"145","author":[{"given":"Johanna","family":"Finkle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian C.","family":"Brost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"R2-20250220","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1146\/annurev-med-043021-014919","article-title":"New frontiers in obesity treatment: GLP-1 and nascent nutrient-stimulated hormone-based therapeutics","volume":"74","author":"Jastreboff","year":"2023","journal-title":"Annu Rev Med"},{"key":"R3-20250220","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","article-title":"Projected U.S. state-level prevalence of adult obesity and severe obesity","volume":"381","author":"Ward","year":"2019","journal-title":"N Engl J Med"},{"key":"R4-20250220","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/ije\/dyz273","article-title":"Has the prevalence of overweight, obesity and central obesity levelled off in the United States? Trends, patterns, disparities, and future projections for the obesity epidemic","volume":"49","author":"Wang","year":"2020","journal-title":"Int J Epidemiol"},{"key":"R5-20250220","first-page":"10.15620\/cdc:106273","article-title":"National Health and Nutrition Examination Survey 2017\u2013March 2020 prepandemic data files\u2014development of files and prevalence estimates for selected health outcomes","author":"Stierman","year":"2021","journal-title":"Natl Health Stat Report"},{"key":"R6-20250220","doi-asserted-by":"crossref","first-page":"578.e1","DOI":"10.1016\/j.ajog.2019.02.013","article-title":"Waist circumference in relation to outcomes of infertility treatment with assisted reproductive technologies","volume":"220","author":"Li","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"R7-20250220","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/oby.20408","article-title":"Relationships between body roundness with body fat and visceral adipose tissue emerging from a new geometrical model","volume":"21","author":"Thomas","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"R8-20250220","doi-asserted-by":"crossref","first-page":"e13023","DOI":"10.1111\/obr.13023","article-title":"Effectiveness of body roundness index in predicting metabolic syndrome: a systematic review and meta-analysis","volume":"21","author":"Rico-Mart\u00edn","year":"2020","journal-title":"Obes Rev"},{"key":"R9-20250220","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/rmb2.12388","article-title":"Are the body shape index, the body roundness index and waist-to-hip ratio better than BMI to predict recurrent pregnancy loss?","volume":"20","author":"Kiremitli","year":"2021","journal-title":"Reprod Med Biol"},{"key":"R10-20250220","doi-asserted-by":"crossref","first-page":"e2415051","DOI":"10.1001\/jamanetworkopen.2024.15051","article-title":"Body roundness index and all-cause mortality among US adults","volume":"7","author":"Zhang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R11-20250220","doi-asserted-by":"crossref","first-page":"e107212","DOI":"10.1371\/journal.pone.0107212","article-title":"Entering a new era of body indices: the feasibility of A Body Shape Index and body roundness index to identify cardiovascular health status","volume":"9","author":"Maessen","year":"2014","journal-title":"PLoS One"},{"key":"R12-20250220","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1210\/clinem\/dgae282","article-title":"A Body Shape Index as a simple anthropometric marker of abdominal obesity and risk of cardiovascular events","volume":"109","author":"Kajikawa","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"R13-20250220","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1097\/AOG.0000000000004395","article-title":"Obesity in pregnancy. ACOG Practice Bulletin No. 230. American College of Obstetricians and Gynecologists","volume":"137","year":"2021","journal-title":"Obstet Gynecol"},{"key":"R14-20250220","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1056\/NEJMra1801040","article-title":"Obesity in pregnancy","volume":"387","author":"Creanga","year":"2022","journal-title":"N Engl J Med"},{"key":"R15-20250220","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s12325-021-01710-0","article-title":"Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists","volume":"38","author":"Ard","year":"2021","journal-title":"Adv Ther"},{"key":"R16-20250220","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/humrep\/del400","article-title":"Obesity and time to pregnancy","volume":"22","author":"Gesink Law","year":"2007","journal-title":"Hum Reprod"},{"key":"R20-20250220","doi-asserted-by":"crossref","first-page":"1085799","DOI":"10.3389\/fendo.2023.1085799","article-title":"GLP-1 receptor agonists for the treatment of obesity: role as a promising approach","volume":"14","author":"Wang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R21-20250220","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"R22-20250220","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity\u2013a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"R23-20250220","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.fertnstert.2021.08.018","article-title":"Obesity and reproduction: a committee opinion","volume":"116","year":"2021","journal-title":"Fertil Steril"},{"issue":"suppl 1","key":"R24-20250220","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ijgo.14538","article-title":"The challenges of obesity for fertility: a FIGO literature review","volume":"160","author":"Gautam","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"key":"R25-20250220","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.2021.4788","article-title":"Diagnosis and management of infertility: a review","volume":"326","author":"Carson","year":"2021","journal-title":"JAMA"},{"key":"R26-20250220","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/humrep\/der416","article-title":"Complications and outcome of assisted reproduction technologies in overweight and obese women","volume":"27","author":"Koning","year":"2012","journal-title":"Hum Reprod"},{"key":"R27-20250220","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/AOG.0000000000000591","article-title":"Risk of adverse pregnancy outcomes by prepregnancy body mass index: a population-based study to inform prepregnancy weight loss counseling","volume":"125","author":"Schummers","year":"2015","journal-title":"Obstet Gynecol"},{"key":"R28-20250220","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1055\/s-0043-1776795","article-title":"Navigating the role of anti-obesity agents prior to pregnancy: a narrative review","volume":"41","author":"Goldberg","year":"2023","journal-title":"Semin Reprod Med"},{"key":"R29-20250220","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1056\/NEJMoa1505297","article-title":"Randomized trial of a lifestyle program in obese infertile women","volume":"374","author":"Mutsaerts","year":"2016","journal-title":"N Engl J Med"},{"key":"R30-20250220","doi-asserted-by":"crossref","first-page":"e13325","DOI":"10.1111\/obr.13325","article-title":"The effectiveness of weight-loss lifestyle interventions for improving fertility in women and men with overweight or obesity and infertility: a systematic review update of evidence from randomized controlled trials","volume":"22","author":"Hunter","year":"2021","journal-title":"Obes Rev"},{"key":"R31-20250220","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.fertnstert.2022.07.020","article-title":"Effects of preconception weight loss after lifestyle intervention on fertility outcomes and pregnancy complications","volume":"118","author":"Hoek","year":"2022","journal-title":"Fertil Steril"},{"key":"R32-20250220","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12902-023-01500-5","article-title":"Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review","volume":"23","author":"Zhou","year":"2023","journal-title":"BMC Endocr Disord"},{"key":"R33-20250220","doi-asserted-by":"crossref","first-page":"e13704","DOI":"10.1111\/obr.13704","article-title":"Anti-obesity pharmacological agents for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 international evidence-based guideline","volume":"25","author":"Goldberg","year":"2024","journal-title":"Obes Rev"},{"key":"R34-20250220","doi-asserted-by":"crossref","first-page":"2042018821989238","DOI":"10.1177\/2042018821989238","article-title":"The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence","volume":"12","author":"Abdalla","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"key":"R35-20250220","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.3390\/biomedicines10081989","article-title":"Therapeutic potential of glucagon-like peptide-1 agonists in polycystic ovary syndrome: from current clinical evidence to future perspectives peptide-1 agonists in polycystic ovary syndrome: from current clinical evidence to future perspectives","volume":"10","author":"Jensterle","year":"2022","journal-title":"Biomedicines"},{"key":"R36-20250220","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1742-4755-8-24","article-title":"Does weight loss improve semen quality and reproductive hormones? Results from a cohort of severely obese men","volume":"8","author":"H\u00e5konsen","year":"2011","journal-title":"Reprod Health"},{"key":"R37-20250220","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"R38-20250220","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/S0140-6736(17)30647-5","article-title":"Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial","volume":"389","author":"Ahern","year":"2017","journal-title":"Lancet"},{"key":"R39-20250220","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"R40-20250220","doi-asserted-by":"crossref","first-page":"e1339","DOI":"10.1210\/clinem\/dgab848","article-title":"New horizons: a new paradigm for treating to target with second-generation obesity medications","volume":"107","author":"Garvey","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"R41-20250220","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11695-022-06332-1","article-title":"2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) indications for metabolic and bariatric surgery","volume":"33","author":"Eisenberg","year":"2023","journal-title":"Obes Surg"},{"key":"R42-20250220","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/AOG.0b013e3181ac0544","article-title":"Bariatric surgery and pregnancy. ACOG Practice Bulletin No. 105. American College of Obstetricians and Gynecologists","volume":"113","year":"2009","journal-title":"Obstet Gynecol"},{"key":"R43-20250220","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"R44-20250220","doi-asserted-by":"crossref","first-page":"e12690","DOI":"10.1111\/cob.12690","article-title":"What is known about the use of weight loss medication in women with overweight\/obesity on fertility and reproductive health outcomes? A scoping review","volume":"14","author":"Maslin","year":"2024","journal-title":"Clin Obes"},{"key":"R45-20250220","doi-asserted-by":"crossref","first-page":"1215356","DOI":"10.3389\/fendo.2023.1215356","article-title":"Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence","volume":"14","author":"Muller","year":"2023","journal-title":"Front Endocrinol"},{"key":"R46-20250220","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jamainternmed.2023.6663","article-title":"Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy","volume":"184","author":"Cesta","year":"2024","journal-title":"JAMA Intern Med"},{"key":"R47-20250220","doi-asserted-by":"crossref","first-page":"JC47","DOI":"10.7326\/J24-0015","article-title":"In T2DM, periconceptional, noninsulin, second-line antidiabetes medications were not linked to major congenital malformations vs. insulin","volume":"177","author":"Egan","year":"2024","journal-title":"Ann Intern Med"},{"key":"R48-20250220","doi-asserted-by":"crossref","first-page":"e083550","DOI":"10.1136\/bmjopen-2023-083550","article-title":"Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six teratology information services","volume":"14","author":"Dao","year":"2024","journal-title":"BMJ Open"},{"key":"R49-20250220","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0140-6736(22)02403-5","article-title":"Contemporary medical, device, and surgical therapies for obesity in adults","volume":"401","author":"Perdomo","year":"2023","journal-title":"Lancet"},{"key":"R50-20250220","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41574-022-00716-0","article-title":"The promise of new anti-obesity therapies arising from knowledge of genetic obesity traits","volume":"18","author":"Hinney","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"R51-20250220","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s13669-023-00350-1","article-title":"Pharmacologic treatment of obesity in reproductive aged women","volume":"12","author":"Nuako","year":"2023","journal-title":"Curr Obstet Gynecol Rep"},{"key":"R52-20250220","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/MED.0000000000000835","article-title":"Glucagon-like peptide-1 receptor agonists and safety in the preconception period","volume":"30","author":"Minis","year":"2023","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"R53-20250220","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"R54-20250220","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"R55-20250220","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jogc.2020.09.023","article-title":"The relationship between pre-pregnancy attempts to lose weight and gestational weight gain: an exploratory primary care prospective cohort study","volume":"43","author":"Piccinini-Vallis","year":"2021","journal-title":"J Obstet Gynaecol Can"},{"key":"R56-20250220","doi-asserted-by":"crossref","first-page":"100065","DOI":"10.1016\/j.obpill.2023.100065","article-title":"Artificial intelligence and obesity management: an Obesity Medicine Association (OMA) clinical practice statement (CPS) 2023","volume":"6","author":"Bays","year":"2023","journal-title":"Obes Pillars"},{"key":"R57-20250220","doi-asserted-by":"crossref","first-page":"100122","DOI":"10.1016\/j.obpill.2024.100122","article-title":"Frequently asked questions to the 2023 Obesity Medicine Association position statement on compounded peptides: a call for action","volume":"11","author":"Bays","year":"2024","journal-title":"Obes Pillars"},{"key":"R58-20250220","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009334.pub2","article-title":"Antenatal interventions for reducing weight in obese women for improving pregnancy outcome","author":"Furber","year":"2013","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"R59-20250220","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"R60-20250220","doi-asserted-by":"crossref","first-page":"103038","DOI":"10.1016\/j.amsu.2021.103038","article-title":"Bariatric surgery and its impact on fertility, pregnancy and its outcome: a narrative review","volume":"72","author":"Pg Baharuddin","year":"2021","journal-title":"Ann Med Surg"},{"key":"R61-20250220","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/GCO.0b013e328332d24e","article-title":"New guidelines for weight gain during pregnancy: what obstetrician\/gynecologists should know","volume":"21","author":"Rasmussen","year":"2009","journal-title":"Curr Opin Obstet Gynecol"},{"key":"R62-20250220","first-page":"213","article-title":"Levels of glucagon-like peptide 1 in hyperemesis gravidarum","volume":"11","author":"Aktulay","year":"2021","journal-title":"Interv Med Appl Sci"},{"key":"R63-20250220","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.3390\/nu15092155","article-title":"Maternal weight management to prevent the developmental programming of MAFLD in offspring of obese mothers","volume":"15","author":"Purcell","year":"2023","journal-title":"Nutrients"},{"key":"R64-20250220","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.3390\/jcm9103213","article-title":"One year's treatment with the glucagon-like peptide 1 receptor agonist liraglutide decreases hepatic fat content in women with nonalcoholic fatty liver disease and prior gestational diabetes mellitus in a randomized, placebo-controlled trial","volume":"9","author":"Vedtofte","year":"2020","journal-title":"J Clin Med"},{"key":"R65-20250220","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2337\/dc16-1017","article-title":"Nonalcoholic fatty liver disease is prevalent in women with prior gestational diabetes mellitus and independently associated with insulin resistance and waist circumference","volume":"40","author":"Foghsgaard","year":"2017","journal-title":"Diabetes Care"},{"key":"R66-20250220","doi-asserted-by":"crossref","first-page":"e2425","DOI":"10.1210\/clinem\/dgac095","article-title":"Incretin hypersecretion in gestational diabetes mellitus gestational diabetes mellitus","volume":"107","author":"Fritsche","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"R67-20250220","doi-asserted-by":"crossref","first-page":"107548","DOI":"10.1016\/j.jdiacomp.2020.107548","article-title":"Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight\/obese women with recent gestational diabetes: a double-blind, randomized, placebo-controlled study","volume":"34","author":"Elkind-Hirsch","year":"2020","journal-title":"J Diabetes Complications"},{"key":"R68-20250220","doi-asserted-by":"crossref","first-page":"10101","DOI":"10.3390\/ijms231710101","article-title":"Incretins as a potential treatment option for gestational diabetes mellitus","volume":"23","author":"Pilszyk","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R69-20250220","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.fertnstert.2022.07.027","article-title":"Nutrition recommendations for a healthy pregnancy and lactation in women with overweight and obesity\u2013strategies for weight loss before and after pregnancy","volume":"118","author":"Hart","year":"2022","journal-title":"Fertil Steril"},{"key":"R71-20250220","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1089\/jwh.2020.8683","article-title":"Obstetrician-gynecologists' strategies for patient initiation and maintenance of antiobesity treatment with glucagon-like peptide-1 receptor agonists initiation and maintenance of antiobesity treatment with glucagon-like peptide-1 receptor agonists","volume":"30","author":"Gill","year":"2021","journal-title":"J Womens Health"},{"key":"R72-20250220","doi-asserted-by":"crossref","first-page":"101351","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol Metab"},{"key":"R73-20250220","doi-asserted-by":"crossref","first-page":"1431292","DOI":"10.3389\/fendo.2024.1431292","article-title":"Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists","volume":"15","author":"Liu","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R74-20250220","doi-asserted-by":"crossref","first-page":"8214","DOI":"10.3390\/ijms25158214","article-title":"Impact of selected glucagon-like peptide-1 receptor agonists on serum lipids, adipose tissue, and muscle metabolism\u2013a narrative review","volume":"25","author":"Szekeres","year":"2024","journal-title":"Int J Mol Sci"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000005825","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T22:01:43Z","timestamp":1740088903000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000005825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000005825","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"2024-09-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}